NASDAQ:ALXO ALX Oncology Q1 2025 Earnings Report $1.31 0.00 (0.00%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$1.36 +0.04 (+3.44%) As of 09/25/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast ALX Oncology EPS ResultsActual EPS-$0.58Consensus EPS -$0.47Beat/MissMissed by -$0.11One Year Ago EPSN/AALX Oncology Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AALX Oncology Announcement DetailsQuarterQ1 2025Date5/8/2025TimeBefore Market OpensConference Call DateThursday, May 8, 2025Conference Call Time7:00AM ETUpcoming EarningsALX Oncology's Q3 2026 earnings is estimated for Friday, November 6, 2026, based on past reporting schedules, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) ALX Oncology Earnings HeadlinesAnalysts Are Bullish on Top Healthcare Stocks: ALX Oncology Holdings (ALXO), Tonix Pharma (TNXP)September 22, 2026 | theglobeandmail.comALX Oncology to Present at Upcoming Investor Conferences in SeptemberSeptember 2, 2026 | globenewswire.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | Porter & Company (Ad)Analysts Have Conflicting Sentiments on These Healthcare Companies: Astrana Health (ASTH) and ALX Oncology Holdings (ALXO)August 8, 2026 | theglobeandmail.comALX Oncology Holdings Earnings Estimates, EPS & Revenue | NASDAQ:ALXO | BenzingaJuly 7, 2026 | benzinga.comALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing RulesJune 30, 2026 | globenewswire.comSee More ALX Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ALX Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ALX Oncology and other key companies, straight to your email. Email Address About ALX OncologyALX Oncology (NASDAQ:ALXO) is a clinical-stage biotechnology company focused on developing therapies that activate the immune system to fight cancer. The company’s approach targets the CD47-SIRPα pathway, an innate immune checkpoint that cancer cells can use to avoid being identified and destroyed by macrophages and other immune cells. ALX Oncology’s lead product candidate is evorpacept, formerly known as ALX148. Evorpacept is an investigational fusion protein designed to block the CD47 “don’t eat me” signal while limiting the binding of normal blood cells. The company has evaluated evorpacept in combination with other cancer treatments, including antibody therapies, across multiple solid-tumor and hematologic cancer settings. The company’s clinical development programs have included studies in head and neck cancer, gastric and gastroesophageal-junction cancer, and other oncology indications. ALX Oncology is headquartered in South San Francisco, California, and has pursued clinical development through collaborations and trials involving research centers and patients in the United States and other regions. As a clinical-stage biotechnology company, its products remain investigational and are not approved for commercial use.View ALX Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/252 Cybersecurity Stocks Breaking Out as AI Continues to Be a TailwindCostco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem5 Scary-Good Stocks With Strong October Catalysts and Breakout PotentialDarden Restaurants Serves Up Fresh Catalysts for a Stock Price RallySoFi Is Bypassing the Banking Bottleneck With Stablecoin Settlement Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
